Entity family

Browse diseases

Named diseases, disorders, syndromes, injuries, and health conditions. Examples include epilepsy, diabetes, stroke.

16articles mentioning diseases

48disease mentions

1distinct diseases extracted

0%of mentions human-reviewed

Active filtersEntity: SLE-DAS ×

SLE-DAS

This disease is selected. Its supporting articles are shown below.

Articles mentioning SLE-DAS

16 articles · page 1 of 2

S13:01 The novel SLE-DAS responder index aligns clinical endpoints with patient experience and outperforms BICLA and SRI-4 in capturing HRQoL: post-hoc analysis in the MUSE, TULIP-1 and TULIP-2 trials

lupusscimed · abstract · 2026-03-01 · 10 matching annotations

93.8%

SLE SLE-DAS MSDA

…ue for HR-QoL supports its use as a next-generation endpoint in SLE trials. SLE-DAS accurately classifies MSDA, supporting use in e…

PO:05:124 Assessment of fatigue and disease activity in patients with systemic lupus erythematosus

lupusscimed · abstract · 2026-03-01 · 7 matching annotations

97.5%

SLE SLE-DAS prednisone corticosteroid (CS) therapy CS therapy

…sociation between disease activity and fatigue in patients with SLE. CS therapy was associated with greater fatigue, regardless of …

S7:05 Ability of SLE-DAS and SLEDAI-2K to predict organ damage accrual in SLE: a real-world 7-year cohort study from Sweden

lupusscimed · abstract · 2026-03-01 · 5 matching annotations

89.6%

Systemic lupus erythematosus SLE-DAS SLE prednisone-equivalent KLURING

…Objectives Systemic lupus erythematosus (SLE) disease activity leads to irreversible organ damage, if n…

LBA:01:19 Real-world feasibility of treat-to-target recommendations in systemic lupus erythematosus: analysis of 321 patients from an academic lupus clinic

lupusscimed · abstract · 2026-03-01 · 4 matching annotations

94.2%

SLE SLE-DAS lupus nephritis prednisone hydroxychloroquine PDN PDN-equivalent PDN-free

…Objectives The 2023 EULAR and 2025 ACR SLE recommendations endorse a treat-to-target (T2T) strategy aiming…

PO:11:288 Anifrolumab for the treatment of refractory systemic lupus erythematosus-associated hypocomplementemic urticarial vasculitis: report of three cases

lupusscimed · abstract · 2026-03-01 · 3 matching annotations

90.2%

Systemic lupus erythematosus SLE-DAS SLE-associated HUVS hypocomplementemic urticarial vasculitis syndrome anifrolumab prednisone

…Objectives Systemic lupus erythematosus (SLE) and hypocomplementemic urticarial vasculitis syndrome (HU…

Anifrolumab in systemic lupus erythematosus: real-world evidence from a Spanish multicentre cohort of 206 patients and literature review

rmdopen · abstract · 2026-03-19 · 2 matching annotations

91.5%

SLE systemic lupus erythematosus SLE-DAS Anifrolumab

…d concomitant therapies, disease activity indices including the SLE Disease Activity Index 2000 (SLEDAI-2K), SLE Disease Activity S…

LBA:01:46 Disease activity is associated with worse fatigue and quality of life in systemic lupus erythematosus

lupusscimed · abstract · 2026-03-01 · 2 matching annotations

92.0%

SLE SLE-DAS corticosteroids immunomodulators treatment Short Form 36 Health Survey

… a key determinant of fatigue and impaired QoL in patients with SLE. Higher activity is consistently associated with worse PROs, pa…

PO:03:088 Risk factors for persistence of cutaneous involvement in systemic lupus erythematosus

lupusscimed · abstract · 2026-03-01 · 2 matching annotations

90.5%

systemic lupus erythematosus SLE-DAS SLE SLEDAI-2K

… among the most frequent and clinically significant features of systemic lupus erythematosus (SLE), occurring in approximately 70–85% of patients during the…

PO:07:189 Clinical and immunoserological profile of SLE patients in Serbia: a two-center cohort analysis

lupusscimed · abstract · 2026-03-01 · 2 matching annotations

85.0%

Systemic lupus erythematosus SLE APS SLE-DAS Sjögren’s disease hydroxychloroquine azathioprine mycophenolate mofetil Clinic of Allergy and Immunology University Clinical Center of Serbia+1 more

…Objectives Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with heterogeneous clinic…

PO:09:247 Anifrolumab in systemic lupus erythematosus with renal involvement: national multicenter registry in clinical practice

lupusscimed · abstract · 2026-03-01 · 2 matching annotations

97.6%

SLE SLE-DAS hidradenitis suppurativa herpes zoster renal involvement mycophenolate mofetil voclosporin tacrolimus belimumab methotrexate+3 more

…hods Observational multicenter study of patients diagnosed with SLE (EULAR/ACR 2019 criteria), treated with ANI who presented renal…

PO:11:289 Real-world effectiveness and glucocorticoid-sparing impact of anifrolumab in systemic lupus erythematosus: montenegrin experience

lupusscimed · abstract · 2026-03-01 · 2 matching annotations

95.9%

SLE SLE-DAS anifrolumab Clinical Center of Montenegro Department of Rheumatology corticosteroids

…ubunit 1, blocks interferon-mediated signaling a key pathway in SLE immunopathogenesis.To describe real-world effectiveness, glucoc…

PO:11:301 Anifrolumab in systemic lupus erythematosus. spanish multicenter registry in clinical practice

lupusscimed · abstract · 2026-03-01 · 2 matching annotations

98.2%

SLE SLE-DAS Kikuchi disease ANI prednisone

…hods Observational multicenter study of patients diagnosed with SLE (EULAR/ACR 2019 classification criteria) treated with ANI. Demo…